Introduction
Aplastic anemia (AA) is a rare disease characterized by the diminished or absent hematopoietic precursors in the bone marrow due to injury to the pluripotent hematopoietic stem cell. AA is successfully treated by bone marrow transplantation (BMT) or by immunosuppressive therapy (IST), usually including anti-thymocyte globulin (ATG) and cyclosporine [1] . Response rates in the range of 60-80% after IST suggest that in the majority of cases AA is an autoimmune disease [2] . In contrast to many other autoimmune diseases, the target of autoimmunity has so far not been elucidated, although some candidate genes have been suggested [3] . Analysis of T lymphocytes in AA patients has identified a pathogenetic role for both CD8 and CD4 T cells [4, 5] . Recent studies have also described antibodies against a variety of auto-antigens in AA patients, although their role in the pathogenesis of the disease remains unclear [6] .
A clinical picture resembling AA may occur in patients with hematological or solid malignancies after
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high-dose chemotherapy and autologous stem cell transplantation. Recent work has demonstrated that antibodies against carbonic anhydrase (CA) may be found in a significant portion of these patients. Interestingly, development of anti-CA antibodies also correlated with regression of the underlying malignant disease, indicating that an autoimmune process may contribute to tumor control [7, 8] .
Antibodies against CA have so far not been described in patients with AA. We aimed to elucidate the incidence and the prognostic significance of anti-CA antibodies in 53 AA patients treated at our institution with ATG or BMT for AA [9] .
Patients and Methods

Patients
Serum samples of patients with AA were collected before and after treatment with ATG or BMT and stored at -80 ° C until analysis. Patients underwent treatment with horse ATG plus cyclosporine or sibling donor BMT at a single institution as described previously [10] . Severity of AA and response to treatment were classified according to established guidelines [11, 12] . Patients gave written informed consent to the analysis, and the study was approved by the local institutional review board.
Detection of Anti-CA Antibodies
The presence of antibodies against 40 ng of commercial human CA I (purchased from Sigma-Aldrich Corporation, St. Louis, Mo., USA) was analyzed by Western blotting of patients' or healthy donors' sera which were diluted 500 times. Bands were quantified using the ImageJ software (http://rsb.info.nih.gov/ij). A patient previously characterized as strongly antibody positive [7] was used as internal reference in each batch of serum samples analyzed (defined arbitrarily as 1 unit). A population of healthy control donor sera was used to establish the lower reference range cutoff (mean + 2 standard deviations).
HLA Typing
Patients from which cryopreserved bone marrow cells were available (n = 42) were typed for the presence of HLA-DR * 15 using a commercial kit employing sequence-specific primers (OneLambda, Canoga Park, Calif., USA).
Statistics
Characteristics of patients with or without anti-CA antibodies were compared by Mann-Whitney U test for continuous or Pearson's 2 test for categorical variables. The impact of antibody positivity on survival was analyzed by Kaplan-Meier analysis. Cumulative incidences of patients responding to treatment were calculated treating death in the absence of response as a competing risk. All p values are two-sided, and were considered significant if ! 0.05.
Results
Fifty-three patients treated for AA between 1980 and 2002 at our institution with ATG (n = 39) or BMT (n = 14) were included in the analysis. Median follow-up of surviving patients in this cohort was 17 years (range 11-24). Pretreatment sera were available in all patients. In the majority of patients (n = 42), one or more posttreatment sera were also analyzed; they had been collected between 1 month and 12 years after initial therapy for AA. The median number of sera analyzed per patient was 5 (range 1-9).
Antibodies against CA Are Frequent in
Patients with AA Before initiation of treatment, antibodies against CA were detectable in 20 patients (38% of the population). Characteristics of patients with and without detectable anti-CA antibodies are summarized in table 1 . Patient gender, etiology of AA, and disease severity were not significantly different between antibody-positive and antibody-negative patients. No difference was found in the frequency of patients carrying HLA-DR * 15, a class II HLA antigen previously found to be overrepresented in AA [13] . Anti-CA-positive patients were older at diagnosis of AA (median 38 years vs. 22 years in anti-CA-negative patients).
In 10 of the patients carrying anti-CA antibodies before treatment (9 treated with ATG, 1 with BMT), followup samples were available. In the patient treated with BMT, antibodies were no longer detectable 6 months after transplantation. In the patients treated with ATG, no clear picture emerged: 3 patients cleared the antibody after ATG and attained hematological improvement (UPN 279, 350, 468) . Notably, in the last patient, the antibody reappeared followed by AA relapse ( fig. 1 a and online suppl. fig. 1 ; for all online suppl. material, see www. karger.com/doi/10.1159/000338826). Three other patients became antibody-negative without hematological improvement (UPN 311, 331, 524). The remaining 3 patients achieved hematological improvement despite continuous positivity for anti-CA antibodies (UPN 569, 625, 646). Evolution of antibody positivity and hematological parameters are summarized in online supplementary figure 1.
Survival and Response to Immunosuppressive Treatment Is Poor in Patients with Anti-CAA Antibodies
Of 39 patients treated with IST, 18 (46%) achieved a complete response, and 12 (31%) a partial response, whereas 9 patients (23%) showed no improvement for a total response rate (CR + PR) of 77%. Analysis of antibody positivity before treatment and response to immunosuppressive treatment showed an unexpected negative correlation. While 16/25 (64%) antibody-negative patients achieved complete response to immunosuppressive treatment, only 2/14 (14%) patients with detectable antibody before treatment responded completely. In contrast, the frequencies of patients showing no improvement to IST were 3/25 (12%) for anti-CA-negative patients, and 6/14 (43%) for anti-CA-positive patients (overall p value = 0.003; fig. 1 b) . Partial or complete responses were also achieved faster in patients without antibody (median time to response 3.6 months) than in patients with anti-CA antibodies (median time to response 6 months; fig. 1 c) .
The detrimental effect of anti-CA antibodies in patients treated with ATG was also evident from survival analysis, which showed a trend towards inferior longterm survival of antibody-positive patients if treated with IST: 10-year survival after ATG treatment amounted to 64 8 10% in antibody-negative versus only 36 8 13% in antibody-positive patients (p = 0.06; fig. 1 d) . 
Clonal Complications
Discussion
This is the first analysis of the incidence of antibodies against CA in patients with AA. CA is a protein that that catalyzes the interconversion of carbon dioxide and water to bicarbonate and protons, and is almost ubiquitously expressed. Anti-CA antibodies have been described in patients with connective tissue diseases such as lupus erythematosus or Sjögren's syndrome [14, 15] . In lupus patients, IgG antibodies that suppress hematopoiesis have been described, although the target they recognize has not been elucidated so far [16] .
While AA is generally considered a T cell-mediated autoimmune disease, several recent studies have shown that AA patients frequently carry autoantibodies. Feng et al. [17] found antibodies against diazepam-binding inhibitor-related protein 1 (DRS-1) in 27/71 (38%) of patients with PNH+ AA and in 2/32 (6%) patients with PNH-AA. Response to IST was 100% in patients with anti-DRS-1 antibodies, but only 55% in patients without anti-DRS-1 antibodies. The same group later demonstrated antibodies against moesin in 25/67 (37%) patients with AA. In contrast to antibodies against DRS-1, antimoesin antibodies were not associated with improved response to immunosuppressive treatment [18] . Most recently, antibodies against heterogeneous nuclear ribonucleoprotein (hnRNP) K were described in 85/273 (31%) AA patients. Response to IST was 87% in antibody-positive patients compared to only 46% in antibody-negative patients. Interestingly, in serial measurements before and after IST, antibody titers against hnRNP K remained strongly positive in patients irrespective of their response to treatment [19] . The presence of these autoantibodies in AA patients does not imply their involvement in the pathogenesis of the disease and may be an epiphenomenon of the autoimmune process. Interestingly, however, an AA patient with multiple autoantibodies (including anti-DRS-1 and anti-moesin) was recently reported to have undergone successful treatment with the anti-CD20-antibody rituximab after failure of IST with ATG and cyclosporine [20] .
The finding that anti-CA antibodies occur after autologous stem cell transplantation in patients showing a clinical picture resembling AA prompted us to study anti-CA antibodies in AA [7] . We show that anti-CA antibodies occur in untreated AA patients at a frequency of 38%, which is comparable to the frequency of antibodies against DRS-1, moesin, or hnRNP K. In contrast to antibodies previously detected in AA patients, presence of anti-CA antibodies was not associated with a better response to IST. In contrast, patients carrying anti-CA antibodies showed poor response to IST. Whether antibodies against CA might serve as a predictive marker of patients with poor response to IST, which might benefit from alternative treatment strategies (i.e. stem cell transplantation), will have to be assessed in future studies.
In conclusion, we show that a significant proportion of AA patients carry antibodies against CA. Half of patients treated with IST become antibody negative after treatment. No correlation was found between posttreatment antibodies and response, and response to IST was poor in anti-CA antibody-positive patients.
